Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7535 in Hepatic Impairment and Normal Hepatic Function
NCT06961643Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Jun 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-7535 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum plasma concentration at Day 4, Area under the concentration curve from time 0 to the last quantifiable concentration at Day 4 and 1 more. Started Jun 2025; status: completed.
02
Drugs
HRS-7535
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06961643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06961643.